Keywords: strong, bioavailability, arpida, iclaprim, swiss, biotechnology, firm

Strong bioavailability for Arpida's iclaprim

Article | 20 February 2006

Arpida, a Swiss biotechnology firm focused on treating severe bacterial infections, has successfully completed a Phase I bioavailability study of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Nystatin

Go to drug listing